2023 Medicare Coverage Offers Insurance To Most Alzheimer’s Patients Taking Leqembi Drugs

2023 Medicare coverage will offer insurance to patients with Alzheimer’s disease who take Leqembi drugs. Unfortunately, some private insurers in some U.S. states announced that they will not cover the drugs with insurance.

The 2023 Medicare coverage intends to offer insurance to most patients with Alzheimer’s disease who takes Leqembi drugs. In addition, the 2023 Medicare coverage will mainly be for individuals ages 65 and older after the Leqembi drugs received full approval in July.

An article in GMToday.com states that the approval for the 2023 Medicare coverage was given after a study revealed that Leqembi slowed the decline in memory and thinking by almost 5 months in contrast to those who take dummy drugs. Reports say Leqembi was developed by Japanese drugmaker Eisai and co-marketed with Biogen Inc.

As a result, the 2023 Medicare coverage will include around 76% of the individuals taking Leqembi. Individuals who are under 65 or as young as their 30s and who are also diagnosed with Alzheimer’s disease will more likely be under the commercial insurance of the 2023 Medicare coverage.

READ ALSO: Medicare Will Have Limited Coverage For A New Class Of Alzheimer’s Drugs Once Fully Approved By The FDA

In Contrast to 2023 Medicare Coverage

However, according to Murphy, in contrast to the 2023 Medicare coverage, some private insurers in the states of New York, North Carolina, and Pennsylvania announced that they will not cover Leqembi with insurance. This is because companies such as Highmark which provides the coverage of Blue Cross and Blue Shield for almost 1.8 million individuals believe that Leqembi is still experimental.

READ ALSO: Medicare Advantage Scam Concerns Raised By Democrats, Activists Demanding Congress To Take Action